Literature DB >> 3940903

Adult respiratory distress syndrome: causes, morbidity, and mortality.

T M Hyers, A A Fowler.   

Abstract

The increased microvascular permeability of the adult respiratory distress syndrome (ARDS) results in multiple organ injury with the lungs and subsequently the kidneys as the principal targets. Direct pulmonary injury, for example aspiration of gastric contents, and indirect injury, for instance abdominal sepsis, can lead to the syndrome. The predominant infectious cause of the syndrome is gram-negative aerobic rods. Even in patients with noninfectious causes of the syndrome, the incidence of subsequent pneumonia and sepsis with gram-negative aerobic rods is high so that these organisms contribute greatly to the morbidity and mortality that result from the syndrome. Activation of polymorphonuclear leukocytes and platelets and proteolysis of complement and coagulation components contribute to the pathogenesis of the syndrome, particularly from the indirect or blood-borne causes. Therapy is largely supportive and has not progressed substantially since the introduction of positive end expiratory pressure with mechanical ventilation. The outlook for recovery of lung function of survivors is generally good, but only one in three with the syndrome survives. Because of the inflammatory properties of the syndrome, current interest for therapy centers on parenteral use of nonsteroidal antiinflammatory agents and prostaglandins of the E and I series.

Entities:  

Mesh:

Year:  1986        PMID: 3940903

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  17 in total

Review 1.  The adult respiratory distress syndrome.

Authors:  N F Voelkel
Journal:  Klin Wochenschr       Date:  1989-06-01

2.  Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84-A resolution.

Authors:  M A Navia; B M McKeever; J P Springer; T Y Lin; H R Williams; E M Fluder; C P Dorn; K Hoogsteen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome.

Authors:  G Zilow; J A Sturm; U Rother; M Kirschfink
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

4.  Endotoxin-induced shock in the rat. A role for C5a.

Authors:  G Smedegård; L X Cui; T E Hugli
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

Review 5.  Acute respiratory distress syndrome ("ARDS"): no more than a severe acute lung injury?

Authors:  R Beale; E R Grover; M Smithies; D Bihari
Journal:  BMJ       Date:  1993-11-20

6.  Gene expression and production of tumor necrosis factor alpha, interleukin 1, interleukin 6, and gamma interferon in C3H/HeN and C57BL/6N mice in acute Mycoplasma pulmonis disease.

Authors:  C B Faulkner; J W Simecka; M K Davidson; J K Davis; T R Schoeb; J R Lindsey; M P Everson
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

7.  Significance of pathologic oxygen supply dependency in critically ill patients: comparison between measured and calculated methods.

Authors:  G Hanique; T Dugernier; P F Laterre; A Dougnac; J Roeseler; M S Reynaert
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

8.  Distribution and function of alveolar cells in multiply injured patients with trauma-induced ARDS.

Authors:  U Pison; M Brand; T Joka; U Obertacke; J Bruch
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

9.  Adult respiratory distress syndrome secondary to end-stage liver disease-successful outcome following liver transplantation.

Authors:  H R Doyle; I R Marino; A Miro; V Scott; M Martin; J Fung; D Kramer; T E Starzl
Journal:  Transplantation       Date:  1993-02       Impact factor: 4.939

10.  Effects of pretreatment with SDZ MRL 953, a novel immunostimulatory lipid A analog, on endotoxin-induced acute lung injury in guinea pigs.

Authors:  H Nakamura; A Ishizaka; T Urano; K Sayama; F Sakamaki; T Terashima; Y Waki; K Soejima; S Tasaka; N Hasegawa
Journal:  Clin Diagn Lab Immunol       Date:  1995-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.